Transplant Infectious Disease and Compromised Host Program and Transplant Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Clin Infect Dis. 2021 Oct 5;73(7):e1302-e1317. doi: 10.1093/cid/ciaa1189.
Successful solid organ transplantation reflects meticulous attention to the details of immunosuppression, balancing risks for graft rejection against risks for infection. The "net state of immune suppression" is a conceptual framework of all factors contributing to infectious risk. Assays that measure immune function in the immunosuppressed transplant recipient relative to infectious risk and allograft function are lacking. The best measures of integrated immune function may be quantitative viral loads to assess the individual's ability to control latent viral infections. Few studies address adjustment of immunosuppression during active infections; thus, confronted with infection in solid organ recipients, the management of immunosuppression is based largely on clinical experience. This review examines known measures of immune function and the immunologic effects of common immunosuppressive drugs and available studies reporting modification of drug regimens for specific infections. These data provide a conceptual framework for the management of immunosuppression during infection in organ recipients.
成功的实体器官移植反映了对免疫抑制细节的精心关注,平衡了移植物排斥的风险与感染的风险。“免疫抑制的净状态”是一个概念框架,涵盖了所有导致感染风险的因素。目前缺乏用于评估免疫抑制移植受者相对于感染风险和同种异体移植物功能的免疫功能检测方法。评估个体控制潜伏性病毒感染能力的最佳综合免疫功能指标可能是定量病毒载量。很少有研究探讨在活动性感染期间调整免疫抑制的问题;因此,在实体器官受者中发生感染时,免疫抑制的管理主要基于临床经验。本综述检查了已知的免疫功能指标以及常用免疫抑制药物的免疫效应,并报告了针对特定感染调整药物方案的研究。这些数据为器官受者感染期间免疫抑制的管理提供了一个概念框架。